A few points for rational conversation.
Every $3 in CYDY stock price = $2.1B in Market Cap.
Bristol Myers, Merck, J&J, Pfizer And the like are 150B-230B companies.
In the past 6 months market darling Monderna went from $7B to $35B. The stock had run from $7B to to ~$15B Mkt Cap on speculation they may “have a cure” and when news came out and trump mentioned the Market Cap spiked about $20B, but some was baked in.
@chet opined he thinks a small cap Bio company typically trades at 10X Future projected revenue. If things went well based on some projections and back of the napkin We we collectively looked before I thought we landed at ~20-25B
My Take: we aren’t going to sniff higher than 25B until such time we are all the way though FDA approval or get a buy out. Over the moon results Combined with support from media and other people in the medical community with an eye towards a fast track approval get us to 13-15B.
that would take us from $5.50 a share to $18
now that being said between short covering and executive branch support and general mania around “the cure for COVID” it’s not imposable that this could get out of hand to the upside. That said anyone saying $50+ a share out of the box Is probably asking a bit much....... but I’d love to be wrong.